Literature DB >> 9949307

Molecular mechanisms of CD8+ T cell-mediated delayed hypersensitivity: implications for allergies, asthma, and autoimmunity.

R S Kalish1, P W Askenase.   

Abstract

Delayed-type hypersensitivity (DTH) is defined as the recruitment of T cells into tissues to be activated by antigen-presenting cells to produce cytokines that mediate local inflammation. CD8+ T cells are now known to mediate DTH responses in allergic contact dermatitis, drug eruptions, asthma, and autoimmune diseases. This inflammatory effector capability of CD8+ cytotoxic T cells was previously poorly recognized, but there is now considerable evidence that these diseases may be mediated by CD8+ DTH. The difference between CD8+ T cells and CD4+ T cells mediating DTH relates to the molecular mechanisms by which antigens are processed and presented to the T cells. Antigens external to the cell are phagocytosed and processed for presentation on MHC class II molecules (eg, HLA-DR) to CD4+ T cells. In contrast, internal cytoplasmic antigens are processed by the endogenous pathway for presentation on MHC class I molecules (eg, HLA-A, -B, and -C) to CD8+ T cells. External allergens can also enter the endogenous pathway to be presented to CD8+ T cells. These include many contact sensitizers, chemical and protein respiratory allergens, viral antigens, metabolic products of drugs, and autoantigens. The resulting CD8+ T-cell response explains the role of CD8+ T-cell DTH mechanisms in allergic contact dermatitis, asthma, drug eruptions, and autoimmune diseases.

Entities:  

Mesh:

Year:  1999        PMID: 9949307     DOI: 10.1016/s0091-6749(99)70489-6

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  29 in total

Review 1.  Yes T cells, but three different T cells (alphabeta, gammadelta and NK T cells), and also B-1 cells mediate contact sensitivity.

Authors:  P W Askenase
Journal:  Clin Exp Immunol       Date:  2001-09       Impact factor: 4.330

2.  Antigenicity and immunogenicity of sulphamethoxazole: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo.

Authors:  D J Naisbitt; S F Gordon; M Pirmohamed; C Burkhart; A E Cribb; W J Pichler; B K Park
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

3.  [Bone marrow hematopoiesis. Evaluation of the myelogram].

Authors:  E B Vladimirskaia
Journal:  Gematol Transfuziol       Date:  1990-08       Impact factor: 0.172

4.  Modulation of PD-L1 and CD8 Activity in Idiopathic and Infectious Chronic Inflammatory Conditions.

Authors:  Louisa Mezache; Cynthia Magro; Craig Hofmeister; Flavia Pichiorri; Douglas Sborov; Gerard J Nuovo
Journal:  Appl Immunohistochem Mol Morphol       Date:  2017-02

5.  CD22 expression mediates the regulatory functions of peritoneal B-1a cells during the remission phase of contact hypersensitivity reactions.

Authors:  Hiroko Nakashima; Yasuhito Hamaguchi; Rei Watanabe; Nobuko Ishiura; Yoshihiro Kuwano; Hitoshi Okochi; Yoshimasa Takahashi; Kunihiko Tamaki; Shinichi Sato; Thomas F Tedder; Manabu Fujimoto
Journal:  J Immunol       Date:  2010-03-24       Impact factor: 5.422

6.  Allergic host defences.

Authors:  Noah W Palm; Rachel K Rosenstein; Ruslan Medzhitov
Journal:  Nature       Date:  2012-04-25       Impact factor: 49.962

7.  CD19 expression in B cells is important for suppression of contact hypersensitivity.

Authors:  Rei Watanabe; Manabu Fujimoto; Nobuko Ishiura; Yoshihiro Kuwano; Hiroko Nakashima; Norihito Yazawa; Hitoshi Okochi; Shinichi Sato; Thomas F Tedder; Kunihiko Tamaki
Journal:  Am J Pathol       Date:  2007-06-07       Impact factor: 4.307

8.  In vitro naïve T cell proliferation failure predicts poor post-immunization responses to neoantigen, but not recall antigens, in HIV-infection.

Authors:  Benigno Rodriguez; Hernan Valdez; Christoph G Lange; Robert Asaad; Kathy Medvik; Scott F Sieg
Journal:  Clin Immunol       Date:  2010-05-15       Impact factor: 3.969

9.  CCR4 expression on host T cells is a driver for alloreactive responses and lung rejection.

Authors:  Vyacheslav Palchevskiy; Ying Ying Xue; Rita Kern; Stephen S Weigt; Aric L Gregson; Sophie X Song; Michael C Fishbein; Cory M Hogaboam; David M Sayah; Joseph P Lynch; Michael P Keane; David G Brooks; John A Belperio
Journal:  JCI Insight       Date:  2019-05-14

10.  Pancreatic carcinoma-specific immunotherapy using synthesised alpha-galactosyl epitope-activated immune responders: findings from a pilot study.

Authors:  Ying Qiu; Mark M Yun; Ming Bao Xu; Yi Zhong Wang; Sheng Yun
Journal:  Int J Clin Oncol       Date:  2012-07-31       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.